CVS Health to break into two, unwinding the Aetna era with a split set for 2028

What happened

CVS Health announced on Wednesday, November 4, 2026 that it will break into two independent, publicly traded companies, separating its retail pharmacy business from its health insurance and pharmacy-benefit operations in one of the largest restructurings the healthcare industry has seen. Chief executive and chairman David Joyner framed the move as a deliberate unwinding of the conglomerate built through acquisition, telling investors, "We're basically taking what I believe is one great company and making it two." The split reverses the 2007 merger with pharmacy benefit manager Caremark and the 2018 purchase of insurer Aetna, a deal valued at $69 billion according to KOCO 5, citing CNN's Chris Isidore, though UPI puts the Aetna price at $78 billion. Shareholders will receive stock in both companies in a transaction structured to be tax-free to shareholders and to CVS Health itself, expected to close in early 2028, with UPI citing the first half of that year.

One company will house Aetna, CVS Caremark, CVS Specialty, Oak Street Health and Signify Health as what the company calls a healthcare solutions provider, led by Joyner as chairman and chief executive. The second entity, CVS Pharmacy, will operate roughly 9,000 US locations, about 800 of them with MinuteClinics staffed by nurse practitioners and physician assistants, under Prem Shah, currently group president of CVS Health. The pharmacy company plans to expand services from its nearly 30,000 pharmacists and to pursue partnerships with payers and drug manufacturers. Goldman Sachs served in an advisory role on the transaction, according to UPI.

The market's first read was cautious. CVS shares, up about 15 percent year-to-date before the announcement, fell 2 percent in premarket trading on Wednesday after an initial uptick on the news. Alongside the split, CVS reported higher third-quarter earnings and revenue, driven primarily by its Health Care Benefits segment, and raised its full-year 2026 adjusted earnings guidance to at least $8.20 per share, up from the prior range of $7.90 to $8.10. The company did not disclose segment-level detail for the pharmacy retail business in the announcement coverage, leaving investors to weigh the two future companies on the strength of the insurance-led results reported Wednesday.

Why it matters

The decision marks the end of a decade-long bet that vertical integration, owning the insurer, the benefit manager and the storefront under one roof, would produce durable advantages in US healthcare. The 2018 Aetna acquisition, at $69 billion by CNN's count or $78 billion by UPI's, was the centerpiece of that strategy, pairing a national insurer with a retail network and a benefit manager to capture more of the drug spending chain. The reversal now underway suggests the model no longer commands the strategic premium it once did, at least in management's judgment.

Regulatory pressure forms the immediate backdrop. Lawmakers in Arkansas and Tennessee have enacted measures over the past two years restricting companies from simultaneously owning pharmacy storefronts and managing drug coverage, a direct challenge to the combined structure CVS pioneered with Caremark and then extended through Aetna. Those state laws do not force the split on their own, but they narrow the room a combined operator has to run both sides of the business, and they signal the direction of travel for other statehouses. The company's reference market value of roughly $117 billion underscores the scale of the separation, and the tax-free share structure signals a clean break rather than a sale, with shareholders holding both successor companies from the outset.

For investors, the raised 2026 guidance of at least $8.20 per share, announced the same day, suggests management wants the split read as strength rather than retreat. The third-quarter beat, driven primarily by the Health Care Benefits segment that will anchor the Joyner-led company, gives that argument its factual footing. Even so, the 2 percent premarket decline shows the market withholding judgment until the two businesses stand alone with their own balance sheets and leadership teams.

How it is being covered

Ground.news counts 47 sources carrying the story, 44 of them rated, with a heavily centrist spread: 91 percent center, 7 percent left and just 2 percent right. Factuality is strong, with 42 of the 44 rated sources scoring high or very high, 13 high and 29 very high, against 2 mixed and 3 unrated. The blindspot sits on the right, where only one right-leaning outlet appears against 40 center and 3 left sources, per Ground.news.

What to watch

Three threads will shape the story between now and the expected close in early 2028. First, regulatory and legislative momentum: additional states may follow Arkansas and Tennessee in restricting combined pharmacy-and-PBM ownership, which could accelerate the separation or complicate the transition for the Caremark benefit-management arm. Second, execution detail: the two companies must complete leadership builds, capital structures and any required approvals, and the exact closing window, early 2028 versus the first half of 2028 per UPI, may firm up in coming quarters. Third, the market's verdict: whether the 2 percent premarket dip reverses as investors weigh a focused insurer against a focused retailer, and whether the raised guidance of at least $8.20 per share holds through the rest of 2026. A fourth item worth tracking is the pharmacy company's partnership strategy, since Prem Shah's plan to expand services from nearly 30,000 pharmacists and court payer and manufacturer deals will define how the 9,000-store network competes once it no longer sits alongside its largest potential customer.

By the numbers

Source snapshot